Evidence map›Paper›PMID 40689741›Full record

ArticleAntimicrobial agents and chemotherapy2025

Exploring the

Patrícia de Almeida Machado, Pollyanna Stephanie Gomes, Juliana da Trindade Granato, Ari Sérgio de Oliveira Lemos, Bruno Vicente, Victor do Valle Midlej, Elaine Soares Coimbra, Herbert Leonel de Matos Guedes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Patrícia de Almeida MachadoDepartamento de Patologia, Faculdade de Medicina, Universidade Federal Fluminense, Niterói, Brazil.ORCID 0009-0009-4223-3690
Pollyanna Stephanie GomesLaboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil.
Juliana da Trindade GranatoNúcleo de Pesquisas em Parasitologia (NUPEP), Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Ari Sérgio de Oliveira LemosNúcleo de Pesquisas em Parasitologia (NUPEP), Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Bruno VicenteLaboratório de Biologia Estrutural, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil.
Victor do Valle MidlejLaboratório de Biologia Estrutural, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil.
Elaine Soares Coimbra *Núcleo de Pesquisas em Parasitologia (NUPEP), Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.
Herbert Leonel de Matos Guedes *Laboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brazil.ORCID 0000-0002-3819-3069

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico PQ-2 (304712/2016-7)Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/201.905/2020Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/202 421/2017Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E-26/202.942/2019
6 · The paper itself

Abstract

Current treatment available for leishmaniasis is fraught with numerous problems, so the search for new treatment alternatives for leishmaniasis is urgent and necessary. The proteasome has been selected as a promising target. Marizomib is a proteasome inhibitor and has shown antitumor effects, with ongoing clinical tests. In this work, we aimed to evaluate the

Indexed as

Antiprotozoal AgentsLeishmania infantumLeishmania mexicanaLeishmaniasis, CutaneousLeishmaniasis, VisceralAnimalsFemaleMiceMice, Inbred BALB CMicroscopy, Electron, TransmissionAntiprotozoal AgentsLeishmania amazonensisLeishmania infantumleishmaniasisMarizomibproteasome inibitors

Identifiers

PMID40689741
PMCPMC12326984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.